Targeting adenosine receptor 2B in triple negative breast cancer

Carola A. Neumann1,2, Kevin Levine1,2, Steffi Oesterreich1,2

1Department of Pharmacology & Chemical Biology, University of Pittsburgh Medical Center Hillman Cancer Center, Womens Cancer Research Center, Magee Womens Research Institute, Pittsburgh, PA 15213, USA.
2Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15261, USA.

Correspondence to: Dr. Carola A. Neumann, Department of Pharmacology & Chemical Biology, University of Pittsburgh Medical Center Hillman Cancer Center, Womens Cancer Research Center, Magee Womens Research Institute, 204 Craft Ave, Pittsburgh, PA 15213, USA. E-mail: neumanncc@upmc.edu


Received: 26 Oct 2017  First Decision: 29 Dec 2017  Revised: 8 Mar 2018  Accepted: 8 Mar 2018  Published: 15 Mar 2018

In the review “Role of adenosine in tumor progression: focus on A2B receptor as potential therapeutic target”, Sorrentino and Morello make a compelling case for considering adenosine 2B receptor (A2BR) as a target in cancer therapy (J Cancer Metastasis Treat 2017;3:127-38). A large body of evidence has accumulated suggesting A2BR to play an active role in tumor immune suppression and metastasis. Thus, this commentary will discuss the intriguing possibility of targeting A2BR in specific breast cancers that express high levels of A2BR and attract infiltrating immune cells.

TRIPLE NEGATIVE BREAST CANCER IS SUSCEPTIVE TO IMMUNE MODULATION

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer that disproportionally affects younger women and those of African origins, compared with Caucasians[1,2]. TNBC is devoid of the three receptors that classify and define most mammary cancers: estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2).[3] The lack of these receptors reduces the efficacy of targeted therapies for this cancer type, limiting treatment options to chemotherapeutic agents, ionizing radiation and surgery. TNBC patients are therefore in dire need for novel targeted therapies.

Breast cancer has long been thought of as a non-immunogenic malignancy. However, a growing body of evidence suggests that this is not the case for all breast cancers. Tumor-infiltrating lymphocytes (TILs) are the most widely studied immune cells and include T cells and B cells. TILs are part of a larger category of infiltrating immune cells that include natural killer (NK) cells, macrophages, neutrophils, dendritic cells,
mast cells and other white blood cells. In breast cancer, TILs play an important role in mediating positive responses to chemotherapy and improving clinical outcomes. Specifically, in patients with HER2-positive breast cancer and TNBC, large adjuvant studies have shown that higher levels of TILs in primary biopsies were associated with prolonged overall survival (OS) and fewer recurrences, independent of therapy⁴⁴. Similar results were also obtained in patient cohorts treated with neoadjuvant therapy. Here, increased levels of TILs in primary biopsies correlated with a higher pathological response rate (pCR)⁵⁶. On the other hand, tumor-associated macrophages (TAMs) that derive from peripheral blood monocytes are recruited to the TNBC tumor microenvironment and undergo activation that leads to the secretion of inhibitory cytokines, the reduction of effector functions of TILs and the promotion of regulatory T cells (Treg)⁹¹. High levels of TAMs are associated with distant metastasis in TNBC in humans and can be blocked by targeting the chemokine ligand 5 (CCL5) in a mouse model¹¹. A growing body of evidence suggests that tumor-infiltrated immune cells from myeloid origin (myeloid-derived suppressor cells, MDSCs) differentiate into cells that promote tumor progression and metastasis in addition to their immunosuppressive role¹³. In a TNBC mouse model it was demonstrated that while monocytic (m)MDSCs infiltrated primarily the primary tumor, granulocytic (g)MDSCs homed to metastases in the lung¹⁵. In humans, gMDSCs were found to increase with neoadjuvant breast cancer therapies in patients showing no pathologic responses¹⁶. Collectively, this suggests that a group of TNBC can benefit from targeted immunotherapies. How can this TNBC patient cohort be identified?

TNBC is a heterogeneous breast cancer. Based on 3247 gene expression profiles, 21 breast cancer data sets have been analyzed that resulted in subtyping of TNBC which has been proven useful to decipher responses of TNBC patients to neoadjuvant therapies¹⁷. For example, patients in the basal-like 1 (BL1) subgroup showed the highest pathological complete response of 41% compared to the basal-like 2 (BL2) and the luminal androgen receptor (LAR) subgroup, 18% and 29%, respectively¹⁷. In addition, classifying then a TNBC cohort (587 patients) in three groups based on the amount of immune cell infiltration in the tumor, allowed to examine an immune signature comprising B- and T-cell markers that include immune-suppressive as well as immune-activating genes in these TNBC subtypes. This analysis revealed that out of all 587 TNBC cases, the ones correlating highest with the immune signature, were found mostly in the BL1 subtype. Interestingly, the M subgroup showed a strong negative correlation (Spearman, -0.95)¹⁷. As the BL1 subtype is characterized by elevated cell cycle and DNA response genes, it may that the higher mutation rate of this TNBC subtype causes aberrant proteins expression that in turn attracts immune infiltrates. In aggregate, this suggests that TNBC patients subtyping by gene expression studies in conjunction with histopathological tissue analyses should be useful for selecting patient cohorts benefitting from immunotherapy.

ADENOSINE RECEPTOR 2B EXPRESSION PLAYS AN IMPORTANT ROLE IN THE TUMOR MICROENVIRONMENT

Four subtypes of G-protein - coupled adenosine receptors exist, designated Adora1 (A1R), Adora2a, (A2AR), Adora2b (A2BR), or Adora3 (A3R), and are classified according to utilization of pertussis toxin - sensitive (A1 and A3) or - insensitive (A2A and A2B) pathways. In the tumor microenvironment, many cell types express A2BR, especially under hypoxic conditions. In neutrophils A1R has a higher affinity for adenosine compared to A2AR or A2BR, and therefore at earlier stages of inflammation, lower local concentrations of adenosine promoted neutrophil recruitment, while later high concentrations of adenosine limit neutrophil recruitment through action of A2AR or A2BR. In dendritic cells (DCs), although other adenosine receptors are expressed, A2BR mediates the differentiation of DCs that behave unlike myeloid DCs as they display impaired allostimulatory activity and express high levels of angiogenic, pro-inflammatory, immune suppressor and tolerogenic factors, including VEGF, IL-8, IL-6, IL-10, COX-2, TGF-β and IDO. Furthermore, A2BR-mediated differentiation of DCs promoted lung tumors in mice. Human
T cells predominantly express A2AR and A2BR, in addition to A1 and A3 receptors. The cAMP-elevating signaling through A2AR or A2BR in T cells results in inhibition of T-cell receptor-triggered activation of T cells and of many effector functions, including proliferation, expansion and secretion by T cells of important anti-tumor cytokines such as IFN-γ and TNF-α\(^2\). Studies in Adora2b\(^{-/-}\) mice revealed that lack of A2BR critically diminished regulatory T-cell (Treg) populations, underscoring the important role of A2BR in T-cell differentiation\(^2\). A2AR as well as A2BR are also expressed on macrophages. Similarly, as found in DCs or T-cells, only A2BR plays a predominant role in the adenosine-dependent differentiation of macrophages. Once activated, macrophages express T-cell suppressing arginase, indoleamine-2,3-dioxygenase and TGF-β and display reduced T cell stimulation which promotes tumor progression\(^2\). The adenosine binding to A2BR results in expansion of the MDSCs pool in tumors and accelerated tumor growth in mice\(^2\). MDSCs expressing A2BR have been successfully targeted with anti-A2BR therapy, suggesting that TNBC patients may benefit from such therapy as well, because they promote TNBC progression\(^2\). In mouse models pharmacological blockade of A2BR reduces tumor burden by activating DCs and improving CXCR3-dependent T cell tumor infiltration in bladder and breast cancer\(^2\). Extensive work in mouse melanoma models has demonstrated that pharmacological A2BR blockade in combination with dacarbazine reduced tumor growth and significantly increased the number of CD8\(^+\) T-cells, decreasing the number of cancer associated fibroblasts this way contributing to decreased melanoma tumor burden\(^2\). In summary, A2BR is an abundant protein in the tumor microenvironment.

**ADENOSINE RECEPTOR 2B FUNCTIONING IN TNBC**

In breast cancer A2AR and A2BR expression varies significantly among breast cancer subtypes. For example, while A2AR expression levels seem similarly expressed among Pam50 subtypes within the METABRIC data set (Molecular Taxonomy of Breast Cancer International Consortium), A2BR expression is significantly higher in basal cancers compared to the other subtypes, such as Her2, LumA and LumB [Figure 2]\(^3\). Expression patterns were confirmed in TCGA (The Cancer Genome Atlas) as well (data not shown; http://cancergenome.nih.gov). Comparing survival among breast cancer patients defined by the Pam50 gene expression, showed that basal-like breast cancers with higher A2BR expression showed shorter
OS and distant metastasis free survival (DMFS) with a median survival for high expressors of 41 and 23 months, respectively. However, patients that expressed high levels of A2BR had a median OS of 95.1 months and a DMFS of 102.6 months, respectively [Table 1]. This is in contrast to high A2AR expression which seems to prolong overall survival in the basal breast cancer group [Table 1]. All in all, these findings suggest a functional difference between these two receptors in basal-like breast cancer. The term basal-like breast cancer is often used as a surrogate for identifying the aggressive TNBC subtype. Close to 80% of the basal like breast cancers are TNBC [31]. As TNBC is defined by lacking ER, PR and HER2, the basal subtype, is characterized by a distinct gene expression signature comprising strong expression of basal markers such as cytokeratins 5,6 and 17 [32].

Evidence already exists that blocking adenosine signaling may be a valuable option in treating TNBC. The A2BR ligand adenosine is produced in sequential action of CD39 and CD73 degrading ATP. Both are surface receptors expressed on cancer cells and like A2BR, induced by oxygen deprivation (hypoxia). In contrast to CD-39, CD73, also known as 5'-nucleotidase, is similar to A2BR, higher expressed in the ER-negative breast cancer population compared to the ER-positive cancers (METABRIC data base; \( P = 3.6e-14 \)). This suggests a close co-operation of the two receptors in TNBC progression. In fact, mouse models have clearly demonstrated that CD73 expression promotes resistance to TNBC to anthracyclins and poor prognosis [33]. This has now been confirmed in human patients as data from the BIG-02-98 study conclude that high levels of CD73 expression on epithelial tumor cells positively associates with reduced DMFS and OS and negatively correlates with tumor immune cell infiltration (Spearman’s \( r = -0.50, P < 0.0001 \)). Patients with high levels of CD73 and low levels of tumor-infiltrating leukocytes had the worse clinical outcome [34]. This suggests that adenosine signaling in TNBC associates with poor patient survival and that targeting CD73 or A2BR may provide a

<table>
<thead>
<tr>
<th></th>
<th>OS log rank</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>P-value</td>
</tr>
<tr>
<td>Low/High</td>
<td>Hazard</td>
</tr>
<tr>
<td>OS log rank</td>
<td>Median OS</td>
</tr>
<tr>
<td></td>
<td>expression</td>
</tr>
<tr>
<td>AR2A</td>
<td>0.012</td>
</tr>
<tr>
<td></td>
<td>40.8/97.5</td>
</tr>
<tr>
<td></td>
<td>0.52 (0.31-0.87)</td>
</tr>
<tr>
<td></td>
<td>0.0008</td>
</tr>
<tr>
<td></td>
<td>18/97.5</td>
</tr>
<tr>
<td></td>
<td>0.42 (0.25-0.71)</td>
</tr>
<tr>
<td>AR2B</td>
<td>0.011</td>
</tr>
<tr>
<td></td>
<td>95.1/41</td>
</tr>
<tr>
<td></td>
<td>1.96 (1.15-3.32)</td>
</tr>
<tr>
<td></td>
<td>0.0004</td>
</tr>
<tr>
<td></td>
<td>102.6/23</td>
</tr>
<tr>
<td></td>
<td>2.16 (1.127-3.67)</td>
</tr>
</tbody>
</table>

Overall survival (OS) and distant metastasis free survival (DMSF) were compared and median survival calculated using km plotter. For OS 241 patients and for DMFS 242 patients were analyzed.

Figure 2. Comparison of A2AR (A) and A2BR (B) expression among Pam50 breast cancer subtypes in the METABRIC. A2BR is significantly higher expressed in basal like breast cancer compared to other breast cancer subtypes (**P = 3.9e-11**). Gene expression data from The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) were downloaded from the Gene expression Omnibus database [GEO: GSE62944] and Synapse software platform (syn1688369; Sage Bionetworks, Seattle, WA, USA), respectively.
promising immunotherapeutic option for a group of TNBC patients. Regulatory T-cell depletion has been recently been shown to potentiate the inhibition of the immune checkpoint in claudin-low breast cancers, a subgroup of breast cancer that is largely found within the TNBC group of patients.[35]

Besides suppressing immune responses in TNBC, some studies suggest a A2BR immune independent function in breast cancer progression. For example, adenosine stimulates proliferation and migration of human TNBC cells through A2BR-mediated stimulation of adenylyl cyclase/PKA and a PLC-dependent Ca(2+) signal[36,37]. Selective pharmacological activation of A2BR promoted tumor cell chemotaxis in vitro and metastasis in vivo using a syngeneic TNBC mouse model (4T1.2 cells). In contrast, the A2BR antagonist PSB1115 reversed significantly both phenotypes. As 4T1.2 cells express exclusively A2BR, the authors concluded that expression on A2BR on cancer cells contributes to breast cancer metastasis.[38]. Mittal et al.[39] confirmed these findings by showing that inhibition of A2RB in vivo, using the 4T1.2 mouse model was independent of CD4+ or CD8+ T-cells and/or natural killer cells in this setting. A synthetic lethality screen identified a pharmacological axis that identifies A2BR as a target gene of the transcription factor Fos-related antigen-1 that promotes TNBC metastasis. In this model, both RNAi silencing and pharmacological inhibition of A2BR inhibited filapodia formation and invasive activity of TNBC cells and correspondingly reduced tumor outgrowth in the lungs in an immune-compromised mouse model[40].

FUTURE DIRECTIONS
Tumor hypoxia is an unavoidable byproduct of fast and aggressive growing tumors, and the hypoxic response is quite robust in TNBC compared to other subtypes.[41]. Deprivation of oxygen induces the accumulation of extracellular adenosine in tumors providing abundant ligand for adenosine receptors, such as A2BR.[25]. A2BR expression is higher in basal-like breast cancers compared to other breast cancer subtypes [Figure 2] and A2BR is a major player in immune suppression, metastasis and relapse in TNBC. Therefore, A2BR provides an attractive target for treating TNBC, for which currently no targeted therapies exist. In particular the combination of immune checkpoint inhibitors together with A2BR agonists should be considered as viable treatment option, as checkpoint inhibitors show promising results in phase 1/2 clinical trials in TNBC.[42]. Besides presenting a viable drug target, A2BR may also serve as a prognostic biomarker in TNBC. More studies need to be done to test this hypothesis. Not unlike in other drug targeting strategies, more research is necessary to develop molecular and pathological parameters upfront that define appropriate patient cohorts that should be tested for anti-A2BR therapies. For example, TNBC subtyping shows how heterogeneous TNBC subtypes are. In addition, analyses are necessary to determine A2BR antagonistic effects on TILs in TNBC and patient outcome. In summary, based on current research, A2BR may present a viable drug candidate in a defined cohort of TNBC breast patients.

DECLARATIONS
Authors’ contributions
Wrote the manuscript: Neumann CA
Developed the METABRIC expression and analysis tool: Levine K, Oesterreich S

Financial support and sponsorship
None.

Conflicts of interest
There are no conflicts of interest.

Patient consent
Not applicable.
REFERENCES


